Company intelligence / Profile preview

EDP Biotech

Knoxville, Tennessee, United Statesedpbiotech.com ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

EDP Biotech developed ColoPlex™, an RUO blood-based diagnostic aid for early detection of colorectal cancers and polyps. The company also provided CRO services for IVD development and operated a CLIA-certified reference lab. In July 2023 it merged with New Day Diagnostics to form a vertically integrated diagnostics entity focused on rapid product development from biomarker discovery through commercialization.

Therapeutic areas: OncologyGastroenterologyInfectious Diseases
Modalities: Diagnostic testImmunodiagnostic test
Industry: Protein Biomarker Diagnostics

Drug pipeline

3 assets

ColoPlex

Commercial

Indications: Colorectal cancer

2 more assets in the full pipeline.

Request access →

Partnerships

Not specifically listed; strategic partnerships referenced post-merger but not named

Beyond the preview

Go deeper on EDP Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDP Biotech.

Explore the full profile